The overall ratings of 13 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Slipping from a C to a D rating, Jazz Pharmaceuticals Plc (JAZZ) takes a hit this week. Jazz Pharmaceuticals Plc is a specialty pharmaceutical company focused on developing and commercializing products to meet medical needs in neurology and psychiatry. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of JAZZ stock.

Astrazeneca PLC Sponsored ADR (AZN) experiences a ratings drop this week, going from last week’s C to a D. Astrazeneca PLC Sponsored ADR is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. For more information, get Portfolio Grader’s complete analysis of AZN stock.

Endo International Plc (ENDP) declines this week from a D to a F. Endo International Plc provides specialty healthcare solutions in the United States and internationally. The company also gets F’s in operating margin growth and return on equity. For more information, get Portfolio Grader’s complete analysis of ENDP stock.

Phibro Animal Health Corporation Class A (PAHC) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of PAHC stock.

Horizon Pharma plc (HZNP) slips from a C to a D this week. Horizon Pharma plc is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of HZNP stock.

This week, Amphastar Pharmaceuticals, Inc.’s (AMPH) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of AMPH stock.

This is a rough week for Dipexium Pharmaceuticals, Inc. (DPRX). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DPRX stock.

Teligent, Inc. (TLGT) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of TLGT stock.

BioDelivery Sciences International, Inc. (BDSI) is having a tough week. The company’s rating falls from a D to a F. BioDelivery Sciences International, Inc. is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BDSI stock.

Novogen Limited Sponsored ADR’s (NVGN) rating weakens this week, dropping to a F versus last week’s D. Novogen Limited Sponsored ADR is a medical services company which develops and markets pharmaceutical products in Australia. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NVGN stock.

This week, Parnell Pharmaceuticals Holdings Ltd. (PARN) drops from a C to a D rating. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of PARN stock.

CymaBay Therapeutics, Inc.’s (CBAY) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CBAY stock.

Acasti Pharma Inc. Class A (ACST) gets weaker ratings this week as last week’s D drops to a F. Acasti Pharma Inc. Class A is a pharmaceutical company that develops drugs for cardiovascular diseases. The company also gets F’s in sales growth, earnings growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACST stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.